Lifibrol: first member of a new class of lipid-lowering drugs?

Bibliography

• FRASER GE: Preventive Cardiology. Oxford University Press, New York (1986).
   Google Scholar
• KANNEL WB: An overview of the risk factors for cardio-vascular disease. In: Prevention of Coronary Heart Disease - Practical Management of The Risk Factors. WB Saunders, Philadelphia (1983).
   Google Scholar
• LAKIER JB: Smoking and cardiovascular disease. Am. J. Med. (1992) 93:8S–12S.
   Google Scholar
• LEVY D, KANNEL WB: Cardiovascular risks: new insights from Framingham. Am. Heart J. (1988) 116:266–272.
   PubMed Web of Science ®Google Scholar
• HEGSTEDT DM: Serum-cholesterol response to dietary cholesterol: a re-evaluation. Am. J. Clin. Nufr. (1986) 44:299–305.
   PubMed Web of Science ®Google Scholar
• KROLEWSKI AS, WARRAM JH, VALSANIA P eta].: Evolvingnatural history of coronary artery disease in diabetes mellitus. Am. J. Med. (1991) 90(Suppl. 2A):565–615.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 pa-tients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389. This trial shows that cholesterol lowering improves survival in patients with coronary heart disease and high baseline cholesterol.
   Google Scholar
• SHEPERD J, COBBE SM, FORD I et a].: Prevention of coronary heart disease with pravastatin in men with hyper cholest erolaemia. New Engl. J. Med. (1995) 333:1301-1307. The benefit of cholesterol-lowering treatment for morbidity and mortality in primary prevention was demonstrated.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al: The effect of pravastatin on the coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. (1996) 335:1001-1009. A convincing study that illustrates the benefit of cholesterol-lowering therapy in secondary prevention even for patients with average cholesterol levels.
   Google Scholar
• GRUNDY SM: HMG-CoA reductase inhibitors for thetreatment of hypercholesterolaemia. New Engl. J. Med. (1988) 319:24–32.
   PubMed Web of Science ®Google Scholar
• ENDO A: The discovery and development of HMG-CoAreductase inhibitors. J. Lipid Res. (1992) 33:1569–1582.
   PubMed Web of Science ®Google Scholar
• HASHIM SA, VAN ITALLIE TB: Cholestyramine resin ther-apy for hypercholesterolaemia. JAMA (1965) 192:289–292.
   PubMed Web of Science ®Google Scholar
• BEST MM, DUNCAN CH, VAN LOON EJ, WATHEN JD: Theeffects of sitosterol on serum lipids. Am. J. Med. (1956) 45:614–622.
   Google Scholar
• STAELS B, VAN TOL A, ANDREU T, AUWERX J: Fibratesinfluence the expression of genes involved in lipopro-tein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. (1992) 12:286–294.
   PubMed Web of Science ®Google Scholar
• SCHOOJANS K, STAELS B, AUWERX J: Role of the peroxisorne proliferator-activated receptor (PPAR) in medi-ating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. (1996) 37:907-925. This paper gives a comprehensive review of the mode of action of fibrates and the role of PPAR in mediating these effects.
   Google Scholar
• SCHLIACK M, LOSER R, SEIBEL K, BLAY KH: Hypolipidaemic activity of K12.148 in rats, marmosets and pigs.Artery (1989) 16:90-104. The first description of the hypolipidaemic effects of lifibrol in animals.
   Google Scholar
• KRAUSE BR, BOUSLEY R, KIEFT K et al: Comparison of lifibrol to other lipid-regulating agents in experime ntalanimals. Pharmacol Res. (1994) 29:345-357. The lipid-lowering effects of lifibrol, gemfibrozil, and lovast atin were compared in various animal models. The authors draw the question-able conclusion that lifibrol belongs to the drug group of the fibrates.
   Google Scholar
• BELL FP, ST JOHN LC: Action of new hypolipidaemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesis, and the fate of injected [14q-acetate. Lipids (1993) 28:1079-1085. Various approaches to examine the effect of lifibrol on cholesterol biosynthesis in rats in vivo and in vitro.
   Google Scholar
• BERGLUND L, SHARKEY MF, ELAM RL, WITZTUM JL: Ef-fects of lovastatin therapy on guinea-pig low density lipoprotein composition and metabolism. J. Lipid Res. (1989) 30:1591–1600.
   PubMed Web of Science ®Google Scholar
• KRAUSE BR, NEWTON RS: Animal models for the evalu-ation of inhibitors of HMG-CoA reductase. Adv. Lipids Res. (1991) 1:57–72.
   Google Scholar
• DINH DM, FUNK GM, VIDMAR TJ, SPILMAN CH: Lifibrol increases hepatic clolesterol 7a-hydroxylase activity in Sprague-Dawley rats. Drug Dev. Res. (1994) 33:439–447.
   Web of Science ®Google Scholar
• SCHLIACK M, KIRCHGESSNER M, LOSER R etal.: Effects of the hypocholesterolemic compound K12.148 on serum lipids and parameters of clinical chemistry of pigs. Animal Physiol. Nufr: (1990) 63:114–119.
   Google Scholar
• SCHLIACK M, LOSER R, SEIBEL K, RATTEL B, LANG G: The hypolipidaemic effect of lifibrol during a long-term treatment of pigs. Artery (1990) 18:1–15.
   PubMedGoogle Scholar
• MYANT NB: Cholesterol in animal tissues. In: CholesterolMetabolism, LDL, and the LDL Receptor. Myant NB (Ed.), Academic Press, Inc., San Diego (1990).
   Google Scholar
• SPADY DK, DIETSCHY JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea-pig, rabbit, ham-ster, and rat. J. Lipid Res (1983) 24:303–315.
   PubMed Web of Science ®Google Scholar
• HASIBEDER H, STAAB HJ, SEIBEL K, SCHMIDLE G, MARZ W: Clinical pharmacology of the hypocholesterolemic agent K12.148 (lifibrol) in healthy volunteers. Eur. Clin. Pharmacol. (1991) 40\(Suppl. 1):S91-S94. Lipid-lowering properties and safety of lifibrol in healthy humans are reported.
   Google Scholar
• TOBERT JA, BELL GD, BIRTWELL J et al.: Cholesterol-low-ering effect of mevinolin, an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. (1982) 69:913–919.
   PubMed Web of Science ®Google Scholar
• NAKAYA N, HOMMA Y, TAMACHI H, GOTO Y: The effectof CS-514, an inhibitor of HMG-CoA reductase, o n se rum lipids in healthy volunteers. Atherosclerosis (1986) 61:125–128.
   PubMed Web of Science ®Google Scholar
• LOCKER PK, JUNGBLUTH GL, FRANCOM SF, HUGHES GS, •FOR THE LIFIBROL STUDY GROUP: Lifibrol: a novellipid-lowering drug for the therapy of hypercholestero-laemia. Clin. Pharmacol. Ther. (1995) 57:73-88. An extensive study on the effect of lifibrol on the relevant lipid parameters, on key sterol intermediates, serum bile acids, and plant sterols. The paper gives a convincing impression of the potency of lifibrol in treatment of hyperlipidaemia.
   Google Scholar
• SCHWANDT P, ELSASSER R, SCHMIDT et al: Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolae:mia. Eur. J. Clin. Pharmacol. (1994) 47:133–138.
   PubMed Web of Science ®Google Scholar
• KOSTNER GM, AVOGARO P, CAZZOLATO G, MARTH E,BITTOLO-BON G: Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis (1981) 38:51–61.
   PubMed Web of Science ®Google Scholar
• DAHLEN GH, GUYTON JR, ATTAR M, FAR GOTTO AM:Association of leve ls of lipoproteinLp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation (1986) 74:758–765.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, WOLF PA, CASTELLI WP, D'AGOSTINO RB: Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA (1987) 258:1183–1186.
   PubMed Web of Science ®Google Scholar
• ERNST E: Plasma fibrinogen- an independent cardiovas-cular risk factor. J. Intern. Med. (1990) 199:365–372.
   Web of Science ®Google Scholar
• WINKLER K, SCHARNAGL H, KLIMA B eta!: The effect oflifibrol (K12.148) on cholesterol biosynthesis, LDL re-ceptor express ion and in vivo s table isotope lipoprotein kinetics. 66th Congress of the European Atherosclerosis Society Florence (1996).
   Google Scholar
• MIETTINEN TA, TILVIS RS, KESANIEMI YA: Serum plantsterols and cholesterol precursor reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol (1990) 131 : 20–31.
   PubMed Web of Science ®Google Scholar
• TILVIS RS, MIETTINEN TA: Serum plant sterols and theirrelation to cholesterol absorption. J Clin. Nutr. (1986) 43:92–97.
   Google Scholar
• VON BERGMANN K, WASSERHESS P, LINDENTHAL et al.:Lifibrol, a potent cholesterol-lowering drug with un-known mechanism(s) of action [Abstract]. Atherosclerosis (1994) 109:326.
   Google Scholar
• KEMPEN HJM, GLATZ JFC, LEUVEN JAG, VAN DEN VOORTHA, KATAN MB: Serum lathosterol concentration is an indicator of whole body cholesterol synthesis in hu-mans. J. Lipid Res. (1988) 29:1149–1155.
   PubMed Web of Science ®Google Scholar
• KOSTNER GM, GAVISH D, LEOPOLD et al: HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation (1989) 80:1313-1319. HMG-CoA reductase inhibitors are suitable for treatment of elevated LDL cholesterol levels rather than combined dyslipidaemia.
   Google Scholar
• FIESELER HG, ARMSTRONG VW, WIELAND eta!: SerumLp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation. Clin. Chim. Acta (1991) 204:291–300.
   PubMed Web of Science ®Google Scholar
• KOPPENSTEINER R, MINAR E, EHRINGER H: Effect oflovastatin on hemorheology in Type II hyperlipoprote-inaemia. Atherosclerosis (1990) 83:53–58.
   PubMed Web of Science ®Google Scholar
• CARLSON LA, HAMSTEN A, ASPLUND A: Pronounced lowering of serum levels of lipoprot ein Lp (a) in hyper - lpidemic subjects treated with nicotinic acid. J. Intern. Med. (1989) 226:271–276.
   PubMed Web of Science ®Google Scholar
• GURAKAR A, HOEG HM, KOSTNER G, PAPADOPOULOSNM, BREWER FIB: Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis (1985) 57:293–301.
   PubMed Web of Science ®Google Scholar
• FARNIER M, BONNEFOUS F, DEVVAS N, IRVINE A: Com-parative efficacy and safety of micronized fenofibrate and simvastatine in patients with primary Type Ha or Ilb hype rlipidemia. Arch. Intern. Med. (1994) 154:441–449.
   PubMed Web of Science ®Google Scholar
• JONES PH, GOTTO AM, POWNALL HJ et al: Effect of gemfibrozil on plasma lipoprotein(a) levels in Type Ha hyperlipoproteinemic subjects [Abstract]. Circulation (1991) 84\(Suppl. 19:11–483.
   Google Scholar
• BIMMERMANN A; BOERSCHMANN C, SCHWARTKOPFF W,VON BAYER H, SCHLEICHER J: Effective therapeutic measures for redwing lipoprotein(a) in patients with dyslipidaemia: lipoprotein(a) in patients with sus-tained-release bezafibrate. CUIT. Ther. Res. (1991) 49:635–643.
   Google Scholar
• MONK JP, TODD PA: Bezafibrate: a review of its pharma-codynamic and phar macokinetic properties, and thera-peutic use in hyperlipidemia. Drugs (1987) 33:539–576.
   PubMed Web of Science ®Google Scholar
• BELL FP: Effect of the lipid-lowering drug lifibrol on lipid metabolism in rat macrophages and in atherosclerotic arteries from swine and WHHL rabbits, in vitro. Biochem. Pharmacol. (1993) 46:1475-1480. The only available data on the effect of lifibrol on lipid metabolism in atherosclerotic tissue and macrophages.
   Google Scholar
• MARZ W, SCHARNAGL H, BIEMER eta].: The mechanism of action of lifibrol (K12.148). Xi International Sympo-sium on Drugs Affecting Lipid Metabolism (1992).
   Google Scholar
• GOLDSTEIN JL, BASU SK, BROWN MS: Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. In: Biomembranes. Part L. Membrane Biogenesis. Fleischer S, Fleischer B (Eds.), Academic Press, Orlando (1983):241–260.
   Google Scholar
• SCHARNAGL H, MARZ W, SCHLIACK H, LOSER R, GROSS
   Google Scholar
• •W: A novel assay for cytosolic 3-hydroxy-3-methylglu-taryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography. J. Lipid Res. (1995) 36:622-627. The manuscript describes the effect of lifibrol on HMG-CoA synthase.
   Google Scholar
• ALBERTS AW, CHEN J, KURON G eta].: Mevinolin: a highly potent competitive inhibitor of hydroxmethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad Sci. USA (1980) 77:3957–3961.
   Google Scholar
• BROWN MS, GOLDSTEIN JL: A receptor mediated path-way for cholesterol homeostasis. Science (1986) 232:34–
   PubMed Web of Science ®Google Scholar
• KOVANEN PT, BILHEIMER DW, GOLDSTEIN JL, JARAMILLO JJ, BROWN MS: Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc. Natl. Acad. Sci. USA (1981) 78:1194–1198.
   PubMed Web of Science ®Google Scholar
• MA PTS, GIL G, SeDHOF TC eta].: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl. Acad. Sci USA (1986) 83:8370–8374.
   Google Scholar
• BILHEIMER DW, GRUNDY SM, BROWN MS, GOLDSTEIN JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolaemia heterozygotes. Proc. Natl. Acad. Sci USA (1983) 80:4124–4128.
   PubMed Web of Science ®Google Scholar
• REIHNER E, RUDELING M, STAHLBERG D eta].: Influence of pravastatin, a specific inhibitor of HMG-CoA reduc-tase, on hepatic metabolism of cholesterol. New Engl. J. Med. (1990) 323:224–228.
   Google Scholar
• MARZ W, BAUMSTARK M, SCHARNAGL H et al.: Accumu-lation of 'small dens' low density lipoproteins in a homozygous patent with familial defective apolipo-protein B-100 results from heterogeneous interaction of LDL-subfractions with the LDL receptor. J. Clin. Invest. (1993) 92:2922–2933.
   PubMed Web of Science ®Google Scholar
• MARZ W, SCHARNAGL H, BIEMER etal: Lifibrol (K12.148) enhances the expression ofLDL-receptors, but has only moderate effects on the mevalonate pathway. 62nd Congress of the European Atherosclerosis Society (1993).
   Google Scholar
• MARZ W, SCHARNAGL H, SCHLIACK M etal.: The effects of lifibrol (K12.148) on cholesterol biosynthesis, LDL receptor expression, and cholesterol absorption. XII International Symposium on Drugs Affecting Lipid Metabo-lism (1995).
   Google Scholar
• BROWN MS, FAUST JL, GOLDSTEIN JL, KANEKO I, ENDO A: Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compact in (ML-236B), a competitive inhibitor of the reductase. j Biol. Chem. (1978) 253:1121–1128.
   PubMed Web of Science ®Google Scholar